Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy Publisher Pubmed

Tavakolpour S^{1, 2, 3} ; Mirsafaei HS² ; Elkaei Behjati S¹ ; Ghasemiadl M¹ ; Akhlaghdoust M⁴ ; Sali S¹

Source: Immunology Letters Published:2017

Abstract

Nucleos(t)ide analogues (NAs) could successfully suppress hepatitis B virus (HBV) replication in patients with chronic hepatitis B (CHB). However, due to probable development of drug resistance or low/delayed response, these treatments may not be satisfactory. In addition to the HBV DNA polymerase inhibiting activity, these drugs could lead to changes in cytokines profiles. It is important to monitor these changes so that they could be used as target of treatment. Evaluating the previously reported immune responses due to NAs treatments, it was concluded that interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-4 (IL-4), and IL-12 increase after the treatment. This will be followed by the improved capacity of immune cells for eliminating HBV. In contrast, regulatory responses including IL-10 and transforming growth factor-beta (TGF-β) significantly decreased as the result of NAs therapy. Unexpectedly, T helper (Th) 17-associated cytokines also decreased significantly. These results could be used to employ the new strategies to suppress viral replication, minimize HBV DNA levels, inducing hepatitis B e antigen (HBeAg) seroconversion or even hepatitis B surface antigen (HBsAg) seroclearance. In order to accomplish these goals, extended treatment with high dose of both IL-12 and IFN in combination with high barrier to resistance NA might significantly improve the HBsAg seroclearance rate. Considering the danger of emerging aberrant immune responses, determining the optimum dosage as well as close monitoring of patients during the treatment is strongly advised. In order to make HBV immunotherapy practical, further studies are needed to confirm these results. © 2017 European Federation of Immunological Societies

Related Docs

View other Related Docs

1. Hepatitis B Immunopathogenesis and Immunotherapy, Immunotherapy (2016)

2. The Possible Role of Interleukin-35 and Its Therapeutic Potential in Pemphigus, International Immunopharmacology (2017)

3. Immune Function of Plasmacytoid Dendritic Cells, Natural Killer Cells, and Their Crosstalk in Hbv Infection, Reviews in Medical Virology (2018)

Experts (# of related papers)

View all Related Experts

Forough Golsaz Shirazi (6)

Fazel Shokri (6)

Other Related Docs

4. Towards Personalized Medicine for Patients With Autoimmune Diseases: Opportunities and Challenges, Immunology Letters (2017)

5. An Overview of the Current Hepatitis B Treatment Strategies After Liver Transplantation, Middle East Journal of Digestive Diseases (2021)

6. The Dual Nature of Retinoic Acid in Pemphigus and Its Therapeutic Potential: Special Focus on All-Trans Retinoic Acid, International Immunopharmacology (2016)

7. Vitamin D Role in Hepatitis B: Focus on Immune System and Genetics Mechanism, Heliyon (2022)

8. The Relationship Between Hla-G and Viral Loads in Non-Responder Hcv-Infected Patients After Combined Therapy With Ifn-Α2α and Ribavirin, Human Immunology (2015)

9. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)

10. Deciphering Host–Virus Interactions and Advancing Therapeutics for Chronic Viral Infection, Viruses (2025)

11. Association of Interleukin-6 and Interleukin-1 Family Gene Polymorphisms in Autoimmune Hepatitis, Annals of Hepatology (2018)

12. Human Leukocyte Antigens Influence the Antibody Response to Hepatitis B Vaccine, Iranian Journal of Allergy# Asthma and Immunology (2015)

13. Characterization of Cd4+ and Cd8+ T Cell Subsets and Interferon Regulatory Factor 4 (Irf4) in Ms Patients Treated With Fingolimod (Fty-720); a Follow-Up Study, Iranian Journal of Allergy# Asthma and Immunology (2018)

14. Optimization of an Efficient Cell Culture Hepatitis B Infection System for Assessment of Hepatitis B Virus Neutralizing Monoclonal Antibodies, Iranian Journal of Immunology (2022)

15. Identification of Occult Hepatitis B Virus (Hbv) Infection and Viral Antigens in Healthcare Workers Who Presented Low to Moderate Levels of Anti-Hbs After Hbv Vaccination, GERMS (2015)

16. Oral Administration of Synthetic Selenium Nanoparticles Induced Robust Th1 Cytokine Pattern After Hbs Antigen Vaccination in Mouse Model, Journal of Infection and Public Health (2017)

17. Construction of a Hepatitis B Virus Neutralizing Chimeric Monoclonal Antibody Recognizing Escape Mutants of the Viral Surface Antigen (Hbsag), Antiviral Research (2017)

18. Association of Il28b (Ifnl3) Rs12979860 Mrna Levels, Viral Load, and Liver Function Among Hcv Genotype 1A Patients, Gastroenterology and Hepatology from Bed to Bench (2019)

19. Role of Th1/Th2 Cells and Related Cytokines in Autoimmune Hepatitis, Turkish Journal of Gastroenterology (2017)

20. T-Cell Engager Antibodies Enable T Cells to Control Hbv Infection and to Target Hbsag-Positive Hepatoma in Mice, Journal of Hepatology (2021)

Style	Citing Format
MLA	Tavakolpour S, et al.. "Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy." Immunology Letters, vol. 190, no. , 2017, pp. 206-212.
APA	Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S (2017). Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy. Immunology Letters, 190(), 206-212.
Chicago	Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. "Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy." Immunology Letters 190, no. (2017): 206-212.
Harvard	Tavakolpour S et al. (2017) 'Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy', Immunology Letters, 190(), pp. 206-212.
Vancouver	Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy. Immunology Letters. 2017;190():206-212.
BibTex	@article{ author = {Tavakolpour S and Mirsafaei HS and Elkaei Behjati S and Ghasemiadl M and Akhlaghdoust M and Sali S}, title = {Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy}, journal = {Immunology Letters}, volume = {190}, number = {}, pages = {206-212}, year = {2017} }
RIS	TY - JOUR AU - Tavakolpour S AU - Mirsafaei HS AU - Elkaei Behjati S AU - Ghasemiadl M AU - Akhlaghdoust M AU - Sali S TI - Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy JO - Immunology Letters VL - 190 IS - SP - 206 EP - 212 PY - 2017 ER -

Science Communicator Platform

Authors

Abstract